Many sponsors seeking for approval for innovative, first-in-class medical devices have found that Economic and Quality of Life (EQoL) studies can be a valuable asset in the overall commercialization process.
Heart failure (HF) is a leading cause of morbidity and mortality worldwide. HF is the underlying cause of >55,000 annual deaths in the US, and the cause of > 1,000,000 annual hospital visits.